Touchlight News and Resources

Touchlight, a contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, has announced the clinical supply of its proprietary dbDNA™ technology to the University of Nottingham. This partnership supports the university’s research and development efforts for a next-generation

Touchlight, an innovation-driven CDMO, has entered into a license agreement with GSK, a leader in biopharmaceutical innovation. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.

LenioBio, a biotech company pioneering cell-free protein production, has entered into a supply agreement with Touchlight, privately-owned CDMO based in London. The collaboration aims to harness Touchlight’s rapid enzymatic doggybone DNA (dbDNA) to accelerate vaccine development within LenioBio’s CEPI-funded project. LenioBio’s

Touchlight, a Contract Development and Manufacturing Organisation (CDMO) based in the UK, has announced a collaboration with the University of Liverpool. The partnership aims to utilise Touchlight’s proprietary doggybone DNA (dbDNA) technology in the development of a personalised DNA vaccine